Abstract
It is recommended to evaluate the presence of latent tuberculosis infection (LTBI) before initiating antitumor necrosis factor α (anti-TNF) therapy for rheumatologic diseases. We aimed to present the follow-up results of 192 patients with rheumatologic diseases before anti-TNF therapy for LTBI. We enrolled 192 patients who were given anti-TNF therapy for their rheumatologic diseases between April 2005 and January 2008. The demographic characteristics of the patients were recorded. Chest X-ray was obtained and tuberculin skin test (TST) was performed in all patients before anti-TNF therapy. LTBI was assessed by detailed history of close contact with infectious cases within the last year, abnormal chest radiography, and positive TST (≥5 mm) before initiating anti-TNF therapy. Patients with anti-TNF therapy were followed with 2-month intervals for active tuberculosis by pulmonary and extrapulmonary symptoms, physical examination, and chest X-ray. Of 192 patients, 104 (54.2%) patients were women, age (mean ± SD) 43.1 ± 12.7 years and 88 (45.8%) patients were men, age (mean ± SD) 39.3 ± 11.2 years. Ninety-one (47.4%) of them had rheumatoid arthritis (RA); 92 (47.9%) had ankylosing spondylitis (AS), and nine (4.7%) had psoriatic arthritis. Isoniazid treatment was started in 129 (67.2%) patients in whom LTBI was detected. No significant difference was observed for TST positivity (TST ≥ 5 mm) between the patients with RA and AS (p = 0.101). Similarly, no significant difference was also observed for TST positivity between the patients who received immunosuppressive therapy and those who did not (p = 0.154). Only three (1.6%) patients developed active tuberculosis at the study period. We suggested that in despite of the presence of rheumatologic disease and/or immunosuppressive therapy, TST is an acceptable and available diagnostic test for detecting LTBI before anti-TNF therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti tumor necrosis factor a therapy. Arthritis Rheum 48:3013–3022
Kroesen S, Widmer AF, Tyndall A et al (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF alpha therapy. Rheumatology (Oxford) 42(5):617–621
Long R, Gardam M (2003) Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168(9):1153–1156
Mutlu G, Mutlu E, Bellmeyer A et al (2006) Pulmonary adverse events of anti tumour necrosis factor-a antibody therapy. Am J Med 119:639–646
Huebner RE, Schein MF, Bass JBJ (1993) The tuberculin skin test. Clin Infect Dis 17:968–975
American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 61:S221–S247
British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60:800–805
Iliopoulos A, Psathakis K, Aslanidis S et al (2006) Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int Tuberc Lung Dis 10(5):588–590
Nizam S, Emery P (2006) Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 65:980
Emery P, Panayi G, Symmons D et al (1984) Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 43:430–434
Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361
Andersen P, Munk ME, Pollock JM et al (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356:1099–1104
Kang YA, Lee HW, Yoon HI et al (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293:2756–2761
Sichletidis L, Settas L, Spyratos D et al (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10(10):1127–1132
Hanta I, Ozbek S, Kuleci S et al (2007) Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα. Clin Rheumatol 26(11):1867–1870
Manadan AM, Joyce K, Sequeira W et al (2007) Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol 25(5):743–745
Gomez-Reino JJ, Carmano L, Descalzo A, BIOBADASER GROUP (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756–761
Mohan AK, Cote TR, Block JA et al (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295–299
Dimakou K, Papaioannides D, Latsi P et al (2004) Disseminated tuberculosis complicating anti-TNF-α treatment. Int J Clin Pract 58(11):1052–1055
Stas P, D’Hoore A, Van Assche G et al (2006) Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol Belg 69(29):217–220
Mayardomo L, Marenco JL, Gomez-Mateos J et al (2002) Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 31(1):44–45
Conflict of Interest statement
Ismail HANTA: None
Süleyman OZBEK: None
Sedat KULECI: None
Ali KOCABAS: None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hanta, I., Ozbek, S., Kuleci, S. et al. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 27, 1083–1086 (2008). https://doi.org/10.1007/s10067-008-0867-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-008-0867-3